Milligan Michael Lee

See RemarksNeumora Therapeutics, Inc. (NMRA) · full profile →Form 4 · filed May 30, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
0 non-derivative · 10 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 28, 2025Disposed to issuer(D)85K0
May 28, 2025Disposed to issuer(D)38K0
May 28, 2025Disposed to issuer(D)29K0
May 28, 2025Disposed to issuer(D)41K0
May 28, 2025Grant(A)400K400K
May 28, 2025Grant(A)85K85K
May 28, 2025Grant(A)38K38K
May 28, 2025Grant(A)29K29K
May 28, 2025Grant(A)41K41K
May 28, 2025Disposed to issuer(D)400K0

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-079926) within minutes of acceptance. Every field above traces to the original document. Verify it directly: